{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:05:53Z","timestamp":1790121953137,"version":"4.0.1"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2023QH267"],"award-info":[{"award-number":["ZR2023QH267"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clon.2026.104314","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:47:34Z","timestamp":1785394054000},"page":"104314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Global Clinical Trial Landscape of Immune Checkpoint Inhibitors in Glioblastoma: Current Status and Future Directions"],"prefix":"10.1016","volume":"58","author":[{"given":"C.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2026.104314_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ejca.2014.12.014","article-title":"Glioblastoma in England: 2007-2011","volume":"51","author":"Brodbelt","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2026.104314_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418790452","article-title":"Treatment of glioblastoma in adults","volume":"11","author":"Wick","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.clon.2026.104314_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clon.2026.104314_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clon.2026.104314_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218125","article-title":"Radiation-induced glioblastoma stem cell-mediated T cell exhaustion via EGR1-Gal3-LAG3 axis in glioblastoma","volume":"636","author":"Huang","year":"2026","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clon.2026.104314_bib6","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149258","article-title":"Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma","volume":"132","author":"Chen","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clon.2026.104314_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100708","article-title":"Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: a phase 2 study","volume":"6","author":"Chen","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.clon.2026.104314_bib8","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clon.2026.104314_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163447","article-title":"Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment","volume":"133","author":"Arrieta","year":"2023","journal-title":"J Clin Invest"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526002852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526002852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:25:59Z","timestamp":1790119559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526002852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":9,"alternative-id":["S0936655526002852"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104314","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global Clinical Trial Landscape of Immune Checkpoint Inhibitors in Glioblastoma: Current Status and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104314"}}